Abstract
Introduction
In-transit cutaneous malignant melanoma metastases remains a difficult and distressing disease. It is a sequela to the primary lesion represented by melanoma deposits between the site of excision and the draining lymph nodes. We present our experience of carbon dioxide ablation of in-transit cutaneous malignant melanoma metastases and discuss the role of laser ablation as first-line management of the disease.
Method
Using a departmental database and case notes, all patients who had undergone carbon dioxide laser ablation for malignant melanoma metastases in the authors’ unit between December 1996 and December 2007 were reviewed.
Results
The total number of lesions ablated was 559 in 16 patients on 91 separate occasions. The mean number of lesions ablated at each treatment was 6 (range 4–200) and the mean number of treatments per patient was 5.7 (range 1–14). All patients had undergone previous surgical procedures for disease control (total 28, range 1–4). Ten patients remained clinically disease-free at 1-year follow-up. Of these ten patients. six achieved remission with a median time from first ablation of 7.5 years (range 2–10 years).
Conclusion
Carbon dioxide laser ablation should be offered as first-line treatment in the management of cutaneous malignant melanoma metastases. A subgroup of patients were clinically disease-free with no systemic progression, following treatment, the reasons for which have not yet been fully explained.
Similar content being viewed by others
References
The World Health Organization (2005)The World Health Organization recommends that no person under 18 should use a sunbed. WHO Media Centre, WHO, Geneva. http://www.who.int/mediacentre/news/notes/2005/np07/en/index.html/. Accessed 6 June 2008
Quinn M, Babb P, Brock A et al (2001) Cancer trends in England and Wales 1950–1999. Studies on Medical and Population Subjects no. 66. The Stationery Office, London
Office for National Statistics (2005) Cancer registration statistics 2002. Registration Series MB1 no. 33. Office for National Statistics, London.http://www.statistics.gov.uk/downloads/theme_health/MB1_33/MB1_33revised.pdf. Accessed 6 June 2008
Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG et al (2001) Final version of the American Joint Committee on Cancer staging for cutaneous melanoma. J Clin Oncol 19:3635–3648
Heenan PJ, Ghaznawie M (1999) The pathogenesis of local recurrence of melanoma at the primary excision site. Br J Plast Surg 52:209–213
Hayes AJ, Clark MA, Harries M, Thomas JM (2004) Management of in-transit metastases from cutaneous malignant melanoma. Br J Surg 91:673–682
Gibson SC, Byrne DS, Mckay AJ (2004) Ten-year experience of carbon dioxide laser ablation as treatment for cutaneous recurrence of malignant melanoma. Br J Surg 91:893–895
Krementz ET, Ryan RF (1972) Chemotherapy of melanoma of the extremities by perfusion: fourteen years clinical experience. Ann Surg 175:900–917
Hill S, Thomas JM (1996) Use of carbon dioxide laser to manage cutaneous metastases from malignant melanoma. Br J Surg 83:509–512
Lens M, Dawes M (2003) Isolated limb perfusion with melphalan in the treatment of malignant melanoma of the extremities: a systemic review of randomised controlled trials. Lancet 4:359–364
Mian R, Henderson M, Speakman D, Finkelde D, Ainslie J, McKenzie A (2001) Isolated limb infusion for melanoma: a simple alternative to isolated limb perfusion. Can J Surg 44:189–192
Strobbe LJA, Nieweg OE, Kroon BBR (1997) Carbon dioxide laser for cutaneous melanoma metastases: indications and limitations. Eur J Surg Oncol 23:435–438
Cribbs RK, Harding PA, Luquette Mark H, Besner GE (2002) Endogenous production of heparin binding EGF-like growth factor during murine partial thickness burn wound healing. J Burn Care Rehabil 23:116–125
Cribbs RK, Luquette Mark H, Besner GE (1998) Acceleration of partial thickness burn wound healing with topical application of heparin-binding EGF like growth factor. J Burn Care Rehabil 19:95–101
Author information
Authors and Affiliations
Corresponding author
Additional information
Presented at the British Medical Laser Association (BMLA) Annual Meeting, Manchester, July 2007.
Rights and permissions
About this article
Cite this article
Kandamany, N., Mahaffey, P. Carbon dioxide laser ablation as first-line management of in-transit cutaneous malignant melanoma metastases. Lasers Med Sci 24, 411–414 (2009). https://doi.org/10.1007/s10103-008-0580-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10103-008-0580-0